secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001411685-25-000011
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen receives US patent for AV-101 to treat neuropathic pain; patent exp. 2034
--------------------------------------------------------------------------------

- USPTO granted patent for oral non-opioid AV-101 covering neuropathic pain, expiring at least 2034.
- Patent strengthens IP for AV-101 targeting disorders involving NMDA receptor, including pain and dyskinesias.
- Preclinical data showed AV-101 similar efficacy to gabapentin/pregabalin with better side effect profile.
- Phase 1 data in Journal of Pain indicated AV-101 well tolerated; allodynia/hyperalgesia reductions observed.
- Vistagen plans to seek strategic partnerships for AV-101 development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000011/0001411685-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000011/vtgn-20250205.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer